- Open Access
Retrospective French nationwide survey of childhood aggressive vascular anomalies of bone, 1988-2009
- Sébastien Héritier1Email author,
- Martine Le Merrer2,
- Francis Jaubert3,
- Michèle Bigorre4,
- Marion Gillibert-Yvert5,
- Benoit de Courtivron5,
- Makram Ziade4,
- Yves Bertrand6,
- Christian Carrie7,
- Pascal Chastagner8,
- Cécile Bost-Bru9,
- Jean-Claude Léonard10,
- Marie Ouache11,
- Liliane Boccon-Gibod12,
- Pierre Mary13,
- Jacques de Blic14,
- Isabelle Pin9,
- Daniel Wendling15,
- Yann Revillon16,
- Véronique Houdoin14,
- Véronique Forin17,
- Hubert Ducou Lepointe18,
- Jane Languepin19,
- Jeanne Wagnon20,
- Ralph Epaud21,
- Brigitte Fauroux21 and
- Jean Donadieu1
© Héritier et al; licensee BioMed Central Ltd. 2010
Received: 17 October 2009
Accepted: 3 February 2010
Published: 3 February 2010
To document the epidemiological, clinical, histological and radiological characteristics of aggressive vascular abnormalities of bone in children.
Correspondents of the French Society of Childhood Malignancies were asked to notify all cases of aggressive vascular abnormalities of bone diagnosed between January 1988 and September 2009.
21 cases were identified; 62% of the patients were boys. No familial cases were observed, and the disease appeared to be sporadic. Mean age at diagnosis was 8.0 years [0.8-16.9 years]. Median follow-up was 3 years [0.3-17 years]. The main presenting signs were bone fracture (n = 4) and respiratory distress (n = 7), but more indolent onset was observed in 8 cases. Lung involvement, with lymphangiectasies and pleural effusion, was the most frequent form of extraosseous involvement (10/21). Bisphosphonates, alpha interferon and radiotherapy were used as potentially curative treatments. High-dose radiotherapy appeared to be effective on pleural effusion but caused major late sequelae, whereas antiangiogenic drugs like alpha interferon and zoledrenate have had a limited impact on the course of pulmonary complications. The impact of bisphosphonates and alpha interferon on bone lesions was also difficult to assess, owing to insufficient follow-up in most cases, but it was occasionally positive. Six deaths were observed and the overall 10-year mortality rate was about 30%. The prognosis depended mainly on pulmonary and spinal complications.
Aggressive vascular abnormalities of bone are extremely rare in childhood but are lifethreatening. The impact of anti-angiogenic drugs on pulmonary complications seems to be limited, but they may improve bone lesions.
Aggressive vascular abnormalities of bone consist of intra-osseous vascular abnormalities leading to osteolysis and, sometimes, extension to adjacent tissues . These diseases are very rare, and affect children and young adults . They may be disseminated or focal, but both forms can be very aggressive and life-threatening. These bone vascular abnormalities are distinct from malignant bone tumors with vascular proliferation, such as angiosarcoma and hemangioendothelioma . In the literature, such entities are variously named "disseminated cystic bone angiomatosis" (mostly multifocal)  and "aggressive massive osteolysis"  (also called Gorham-Stout disease if unifocal). Some authors use the name Gorham-Stout disease for multifocal cystic bone angiomatosis [6–12], and nearly ten other names have also been used. A recent review of 43 cases of vascular lesions of bone recommended the use of the ISSVA classification .
The natural history of such diseases is mainly known through individual case reports, and there are only two series with more than 10 patients (15 and 11 cases)[13, 14]. The lack of epidemiological data, together with the conflicting nature of available information, especially on the natural history and patient management, led us to conduct a retrospective study of cases diagnosed in France during the past 21 years. Here we report the epidemiological, clinical and biological characteristics, treatment modalities and outcome.
Patients and Methods
All children (age <18 years at diagnosis) with a diagnosis of aggressive vascular abnormalities of bone (including "bone angiomatosis" and "Gorham-Stout disease") between 1 January 1988 and 1 September 2009 and managed in a French hospital were eligible for the study. We contacted all pediatricians belonging to the Society of Pediatric Hematology-Immunology and the French Pediatric Cancer Society, including orthopedic surgeons in French teaching hospitals. The diagnosis of aggressive vascular abnormalities of bone was based on histological examination of a bone lesion. A presumptive diagnosis could be made in the following circumstances: Situation A: bone osteolysis and chylous pleural effusion, with or without pulmonary lymphatic infiltration; and situation B: isolated bone osteolysis, provided Langerhans histiocytosis and infectious bone abscess were ruled out. In this latter case the diagnosis was based on three criteria: 1) the site of involvement (vertebra, ribs, pelvis and scapular belts); 2) few if any bone symptoms, in the absence of complications (fracture, including vertebral collapse); and 3) the following characteristic aspect on roentgenography or magnetic resonance imaging (MRI): well-defined piecemeal lesions; centromedullary and cortical involvement with no periosteal reaction; pseudocystic aspect and ring-shaped peripheral contrast uptake with secondary filling. In the absence of histological documentation, patients with osteolysis involving solely the feet and hands, and patients with associated renal disease , were excluded, as were patients with isolated pulmonary chylothorax and lymphangiectasis.
Multifocal osseous forms are defined as those in which osteolysis affects several bone segments distant from one another, with healthy bone in-between. Localized osseous forms are defined as those in which osteolysis affects only one bone with contiguous lesions, or several anatomically contiguous bones.
The date of diagnosis was the date of biopsy when relevant. For presumptive diagnoses, the date of diagnosis was the date of X-ray examination showing typical lesions. The date of first symptoms was the date when the first manifestations potentially related to the disease were reported by the patient or the family. Clinical remission is defined as the absence of any complication for at least two years. The following criteria were used to evaluate therapeutic efficacy: i) symptomatic lesions (dyspnea due to pulmonary involvement, clinically assessable cutaneous, subcutaneous or soft-tissue involvement): efficacy was judged at 3 months, based on changes in respiratory status or stabilization of lesion volume; ii) in the absence of symptomatic lesions (solely radiological signs of bone involvement or asymptomatic involvement of a deep organ [spleen]), efficacy was judged at 2 years, based on the occurrence of complications. Complications were defined as follows: bone fractures; vertebral collapse; consequences of tissue destruction due to proliferation of pathological tissue and necessitating hospitalization; and all other serious complications. Serious complications included disseminated intravascular coagulation; respiratory failure due to pleural effusion, or lung lymphangiectasis and vertebral collapse with neurological complications.
The following data were systematically collected from the patients' files: clinical information, i.e. personal and family history, symptoms; histology; biology; and imaging studies (including radiography of the lesions, MRI, scintigraphy, and bone densitometry). Treatments and complications were recorded from diagnosis to the last visit. No further examinations were requested for this solely observational study. Cases #10, #12 and #13 have been partially reported elsewhere [16–18]. The Kaplan-Meier method was used to estimate survival rates. The endpoint for the survival analysis was death. The period taken into account was the interval between the date of diagnosis and the event (or the last examination when no event occurred). The cut-off date was 15 September 2009.
Characteristics of the patients
There were 8 girls and 13 boys Table S1, Additional file 1. Two children originated from North Africa (including a French resident), one was from Italy, and the other 18 children were of French origin. No parental consanguinity was found, and there was no known family history of aggressive vascular abnormalities of bone, or other vascular abnormalities. Patient #1 had had a hemangioma during infancy that regressed spontaneously. Two children were born prematurely (30 and 34 weeks). Patient #18 had a dominant form of familial exostosis, as did his mother. This patient was mentally retarded and had had three severe bacterial infections (pneumococcal meningitis, osteomyelitis due to betahemolytic streptococci, and Staphylococcus aureus pneumonia). Patient #12 was also mentally retarded and patient #7 had partial epilepsy.
Mean age at diagnosis was 8.0 years [0.8 to 16.9 years]. No clear triggering factors were identified. Two patients had suffered trauma close to the affected areas, more than two years previously. Four other patients had had infections in the region of the affected areas: patient #16 contracted mumps less than two months before onset, which was revealed by laterocervical tumefaction; patient #10 had had pleurisy and pneumococcal purulent pericarditis at age 4 years (9 years before the diagnosis of thoracic angiomatosis); patient #18 had had bilateral lymphatic pleural effusion after an episode of pneumonia associated with Staphylococcus aureus bacteremia; patient #3 had recurrent purulent meningitis (due to Haemophilus influenza e), revealing a meningeal defect at the third episode, leading to the diagnosis of aggressive vascular abnormalities of bone.
Diagnosis and clinical manifestations
Pathological examination confirmed the diagnosis in 16 cases, on a sample of a bone lesion in 15 cases and of involved skin and spleen tissue in a patient with bone lesions. In three cases (#1, #3 and #7), a second biopsy was required for diagnosis. In case #9 an aggressive vascular abnormality of bone was diagnosed after re-examining the initial specimen, 6 years after misdiagnosis of Langerhans histiocytosis. In case #4 and #20 the only bone biopsy was non contributory. In cases #8 and #11, two biopsy procedures were complicated by heavy bleeding (including a case of pulmonary hemorrhage) and the diagnosis remained presumptive. These two cases were diagnosed on the basis of a combination of typical bone lesions and pleural effusion or lymphangiectasis on pulmonary CT, corresponding to presumptive diagnosis (situation A). In cases #2, #4 and #20 the diagnosis remained presumptive (situation B).
The median interval between the first clinical manifestations and the diagnosis of aggressive vascular abnormalities of bone, assessable in 18 patients, was 0.47 years (range 0.01-10.3 years). In nine cases, at least 6 months elapsed between the discovery of osteolysis and the diagnosis of aggressive vascular abnormalities of bone. Three patients initially received specific chemotherapy (vinblastine and steroids) for suspected Langerhans histiocytosis, to no effect. The first sign of the disease was an acute complication in 13 of the 21 patients, consisting of pathological fractures (n = 4), cyphosis due to vertebral collapse (n = 1), dyspnea (n = 7) due to abundant pleural effusion (n = 5) or to respiratory failure with pulmonary lymphangiectasis (n = 2), or meningitis due to an osteomeningeal breach (n = 1) [Table S1, Additional file 1]. One case was revealed by chronic lumbosacral pain and one by a persistent limp, while one case was diagnosed during investigation of chronic lumbago associated with growth retardation. Three patients presented with subcutaneous tumefaction and one case was diagnosed at age 7 years, during follow-up of a cervical lymphangioma, diagnosed at birth, which relapsed once at age 2 years and was then complicated by spleen involvement; later radiographs showed vertebral, scapular and iliac lesions. Finally, in one case the disease was diagnosed on radiographs prescribed for facial trauma following a vagal malaise.
The two most frequently affected bone sites were the spine (16 cases, especially the dorsal spine), and the ribs (12 cases). The other sites, in order of decreasing frequency, were the pelvis, cranium, femur and humerus.
Sixteen patients had multifocal osseous forms at diagnosis. Six patients had more that 9 affected bone segments, including a child with 13 sites (case #6) [Table S1, Additional file 1]. Five patients had localized forms: two had lesions localized to the pelvis and lower limbs (cases #2 and #5) while the other three had lesions localized to the thoracic cage (ribs, dorsal spine and sternum; cases #10, 12 and #13).
Among the five patients with localized forms, the three who had lesions localized to the thoracic cage developed lung involvement.
Imaging and laboratory findings
In addition to symptomatic treatments, three therapeutic approaches were attempted, namely radiotherapy, cytostatic drugs (including vinca alkaloids and steroids), and antiangiogenic drugs (α interferon, bisphosphonates, thalidomide and bevacizumab) [Table S2, Additional file 1]. Treatment was tailored to the individual patients. We analyzed treatment efficacy according to the affected organs, as each site of involvement presents different targets and therefore different methods of assessment.
Management of patients with symptomatic pulmonary involvement (n = 9) consisted of routine pleural drainage, with octreotide infusion in 4 cases and surgical shunting in 3 cases. In one case (case #13) drainage alone was sufficient to prevent further relapses. Various curative treatments were attempted in refractory forms: radiotherapy of the chest wall or a lung half-field (n = 4), chemotherapy with vinca alkaloids (vincristine and vinblastin) (n = 3), and interferon alfa, with or without a bisphosphonate or thalidomide (n = 4) and finally bevacizumab in one case. Pleural radiotherapy was administered at individually tailored doses. Four cases of pleural effusion were treated with chest irradiation at doses of 49.5 Gy in case #12 (unilateral), 18 Gy (right)+ 12 Gy (left) in case #11, 18 Gy in case #8 (unilateral) and 8.5 Gy in case #14 (unilateral). The three patients treated with the highest doses have had no recurrent effusion during more than 8 years of follow-up, but they have severe orthopedic sequelae. Patient #8, after a marked clinical improvement at 6 months, remained stable until the recurrence of pleural effusion with intrapulmonary lymphangiectasis 8 years later, but the pleural effusion relapsed at this time. This relapse was refractory to a combination of α interferon and thalidomide. The patient treated with a lower dose (8.5 Gy) died within two months, with no improvement in the pleural effusion. Two patients were treated with vinca alkaloids (vincristine (n = 2) and vinblastine (n = 1); at least six injections), combined with oral steroids (40 mg/m2/d for 4 weeks). No improvement was observed in either case. Four patients received α interferon, one in combination with zoledronate, one in combination with pamidronate and one in combination with thalidomide. The patient treated with α interferon alone (case #15) had systemic toxicity, leading to treatment withdrawal after 83 days with no improvement. The patient treated with α interferon and pamidronate (case #19) showed no improvement. The patient treated with α interferon and thalidomide (case #8) was refractory and died at month 2. Finally, only the patient (case #18) treated with α interferon and zoledronate showed an improvement in pleural effusion, at month 3, but the pleural effusion relapsed at month 9 and was not sensitive to bevacizumab.
Management of seven patients with skin and subcutaneous lesions or subcutaneous tumor was also very diverse. Three patients received radiotherapy. In patient #11, a subcutaneous lesion of the left hemithorax disappeared after 6 months of radiotherapy (12 Gy) prescribed for pleural effusion, while patient #14 and #15 showed no improvement following 8.5 Gy and 15 Gy. One patient (#9) received the standard treatment for Langerhans histiocytosis (12 injections of vinblastine and steroids 40 mg/m2) for 6 months, to no effect. Two patients were treated with α interferon alone: Patient #15 was treated for 83 days with no measurable effect, and patient #16 was treated for at least 3 months and had no measurable improvement. Two patients received a bisphosphonate, with or without α interferon: Patient #4 (treated with zoledronate 0.05 mg/kg IV every 3 months) had no measurable improvement. Patient #9 was treated with etidronate (400 mg/d) and α interferon (2.5 × 106 U/m2 three times a week), and the supraclavicular and cervical extension appeared to remain stable during 9 months of follow-up.
Involved bone was a target of systemic treatments in 10 patients but the short-term response was difficult to assess because it was usually asymptomatic, except in case of fracture. In addition to local treatments, only α interferon and/or bisphosphonates were tried in these ten cases. In seven cases (#2, #3, #4, #9, #18, #19, #20) no bone complications have occurred, but these patients have less than two years of follow-up. In patient #1, treated with α interferon (1.5 × 106 U five times a week then tapered to three times a week) secondarily combined with pamidronate, no bone complications have occurred with more than two years of follow-up. Finally, new fractures occurred during long-term pamidronate therapy in patient #6 and during long-term pamidronate/zoledronate and α interferon in patient #7.
Embolization (case #13) and sclerotherapy (case #16 and #17) were also attempted in three cases but only patient #17 showed an improvement. Surgery aimed at resecting all angiomatous tissue was never attempted in this series.
Complications, outcome and prognosis
The disease progressed either gradually or discontinuously, with periods of stabilization and symptom disappearance followed by new complications. However, it was difficult to identify disease progression formally, as regular evaluations were not performed.
Nine patients had respiratory complications leading to respiratory distress, which was fatal in five cases. Respiratory distress was secondary to pleural effusion or to an exacerbation of pulmonary lymphangiectasis. Spinal complications, including vertebral collapse, occurred in 10 patients. They were generally mild but were accompanied by spinal cord damage in two cases, with one death by cervical cord section and one case of permanent paraplegia. Pathological fractures occurred in 8 patients. Finally, one patient had recurrent meningitis due to an osteomeningeal breach secondary to skull base involvement. Biological signs of disseminated intravascular coagulation were observed in five cases and lasted several months.
Six patients died (29%). The survival rate 10 years after onset was 71% (95%CI 43-87%) but the curve has not yet plateaued. The six deaths occurred between 3 months and 16.9 years after onset (median 2.4 years). The causes of death were pulmonary involvement (5 cases) and spinal involvement (1 case).
Four patients are in persistent clinical remission, with an active phase of 1 year (#11), 4 years (#12), 10 years (#7) and 13 years (#13). Three of the four patients in remission have severe sequelae, consisting of radiotherapy-induced scoliosis in two cases and paraplegia secondary to vertebral collapse in one case.
This retrospective survey identified 21 cases of aggressive vascular abnormalities of bone in children over a 21-year period in France. Despite the small number of cases, this is the largest pediatric series published to date. We used a national network of specialists in pediatric hematology-oncology and including pediatric orthopedists, as most patients present with what resembles a bone tumor and are thus referred to such specialists. Although we cannot be sure we identified all French cases, it is unlikely that the true number of cases was much higher, and the prevalence of the disease probably corresponds to that of extremely rare conditions, i.e. between 0.1 and 1 case per million children less than 15 years of age. There was a male predominance in our series, as reported in the literature [2, 14]. We found no familial cases and no consanguinity. No intercurrent disorders were present in 20 of the 21 patients. The association with dominant familial exostosis is noteworthy, even if no clear link has been found between the two disorders. The diagnosis of the disease in 3 cases after bacterial infections of the same serous membrane is intriguing, but no conclusion can be drawn from this observation alone. Most patients presented with symptoms linked to bone lesions (fractures) or to pulmonary involvement. In three cases the initial diagnosis was Langerhans histiocytosis and the patients received the relevant treatment before the diagnosis was corrected (notably in view of the lack of therapeutic efficacy).
This series comprised multifocal forms with cystic intraosseous lesions seen on imaging studies (n = 16), and localized forms (n = 5), corresponding to the two previously identified forms of « osseous angiomatosis », namely multifocal cystic osseous angiomatosis for multifocal forms and aggressive massive osteolysis (aka Gorham-Stout disease) for unifocal forms. Careful appraisal of the patients' medical history and imagery shows, however, that there is no clear basis for the distinction between these two forms. The 5 patients initially considered as having localized disease resembled the patients with multifocal forms, with respect to demographic characteristics and outcome (especially secondary pulmonary extension and mortality). One of our patients (case #14) was considered to have localized involvement (thoracic cage), complicated by pleural effusion, but autopsy revealed the presence of abnormal vascular tissues in the skull and pelvis and urinary bladder. Moreover, not all the patients had radiographic studies of the entire skeleton, as in some "localized" forms reported in the literature. Thus, in the absence of precise biological, pathological or even radiological criteria, we suggest that all patients should be considered to belong to a single nosologic entity. In future studies of aggressive vascular malformations of bone, the diagnostic work-up should systemically include all bones and lung CT.
Diffuse bone demineralization was observed in ten of the eleven assessable cases. This phenomenon has also been reported in the literature  and supports the current view that the osteolysis is related to osteoclast hyperstimulation [15, 20, 21].
Pathological specimens were reviewed in 7 cases. The bone lesions were composed of abnormal non fenestrated sinusoids with continuous wall CD31 positivity. Lung lesions showed subpleural and peribronchial dilated lymphatic cavities, sometimes with smooth muscle bundles in the walls. Spleen lesions showed disseminated cystic cavities of non fenestrated CD31-positive sinusoids with surrounding smooth muscle. Skin lesions were mainly hypodermic, with foci of cystic lymphatic D2-40 positive and venula CD31 positive abnormal aggregation. In summary, aggressive vascular abnormalities of bone lesions mainly consisted of capillarized sinusoids in bone marrow and spleen and abnormal lymphatics with smooth muscle lining in lung, pleura and skin. A recent study showed that these capillarized sinusoids are CD 105 (endoglin)-positive, like the bone of growth plate capillaries . Among aggressive vascular abnormalities of bone, it is difficult to distinguish between venous and lymphatic subtypes, as suggested in Bruder's recent review article . Likewise, the literature contains numerous borderline forms between predominantly venous and predominantly lymphatic forms. Immunohistochemical studies, especially those focusing on CD31 (an endothelial marker), CD34 (expressed by blood vascular endothelial cells), D2-40 and LYVE-1 (lymphatic endothalial cells), markers of vascular proliferation such as the MIB1 proliferative index and VEGF expression within the lesions, would appear to be more useful for subdividing, or on the contrary uniting, these pathological entities. We recommend grouping together these disorders under the term « aggressive vascular abnormalities of bone », instead of the older term « angiomatosis of bone», as the « oma » suffix is suggestive of tumor proliferation.
In this study, neither chemotherapy with spindle poisons nor steroid therapy at a dose of 40 mg/m2 was beneficial. Thirteen patients received α interferon (n = 8) and/or bisphosphonates (n = 10). Only six cases treated with α interferon, associated with bisphosphonates in 3 cases, have been reported in the literature [Table S3, Additional file 1] [9, 10, 23–26]. We observed only short-term efficacy in one patient with pleural effusion (#18), whereas the literature describes four cases of successful treatment and one failure [Table S3, Additional file 1]. The value of α interferon-bisphosphonates combinations in this setting remains to be determined. These treatments, especially after prolonged administration, appeared more effective for preventing bone complication and limiting the osteolytic process, as observed in two cases (#1 and #7), but the other cases have insufficient follow-up. Currently, there is no clinical basis on which to choose a particular bisphosphonate.
High-dose thoracic radiotherapy (at least 18 Gy) had a durable impact on pleural effusions, but two children thus treated developed severely incapacitating scoliosis and a relapse was observed in 1 of 3 cases after 8 years. In contrast, a dose of 8.5 Gy was not effective. Thus, it seems that high doses must be used in this setting. Indeed, other authors have recommended doses between 25 and 45 Gy [27–30]. Fractionated bone radiotherapy at a total dose of 25 to 40 Gy can stop the osteolytic process [31–34], but failures have also been published [2, 23, 35, 36]. None of our patients underwent surgery aimed at resecting all the vascular abnormal tissue. Surgical treatments had variable results, and bone grafts during the active phase of the disease have a tendency to be resorbed [11, 31, 37].
In our series the vital prognosis depended on pulmonary and spinal involvement. Special attention must be paid to localized forms affecting the thoracic cage, as they carry a high risk of pulmonary complications. Pulmonary complications such as pleural effusion have already been reported in the literature, with an estimated incidence of between 17% and 25% [9, 38]. In contrast, 47% of our patients presented with radiographic and/or clinical signs of pulmonary lymphangiectasis or pleural effusion. We observed five cases of pulmonary lymphangiectasis, characterized in four cases by respiratory failure and associated with pleural effusion; no clinical manifestations occurred in the last case.
Aggressive vascular abnormalities of bone are rare but potentially life-threatening disorders of unknown etiology. Localized forms and multifocal cystic bone forms are very similar, and there seems to be no reason to consider them as distinct entities. Pulmonary involvement is a major prognostic factor. The efficacy of antiangiogenic treatments and of third-generation bisphosphonates such as zoledronate is unclear and must be further evaluated. Molecular biology-based approaches, including immunolabelling of bone lesion samples, should help to understand these disorders and to orient the choice of treatment.
The authors thank David Young for editorial assistance and the French Histiocytosis Association. This study was supported by grants from Groupe d'étude des histiocytoses, and the Histiocytosis Reference Center. We also thank the patients and their families for their participation in this study, and Mr J.P. Grignet and Ms D. Sommelet.
- Gorham LW, Stout AP: Massive osteolysis (acute spontaneous absorption of bone, phantom bone, disappearing bone); its relation to hemangiomatosis. J Bone Joint Surg Am. 1955, 37-A: 985-1004.PubMedGoogle Scholar
- Choma ND, Biscotti CV, Bauer TW, Mehta AC, Licata AA: Gorham's syndrome: a case report and review of the literature. Am J Med. 1987, 83: 1151-6. 10.1016/0002-9343(87)90959-4.View ArticlePubMedGoogle Scholar
- Bruder E, Perez-Atayde AR, Jundt G, Alomari AI, Rischewski J, Fishman SJ, Mulliken JB, Kozakewich HP: Vascular lesions of bone in children, adolescents, and young adults. A clinicopathologic reappraisal and application of the ISSVA classification. Virchows Arch. 2009, 454: 161-79. 10.1007/s00428-008-0709-3.View ArticlePubMedGoogle Scholar
- Brower AC, Culver JE, Keats TE: Diffuse cystic angiomatosis of bone. Report of two cases. Am J Roentgenol Radium Ther Nucl Med. 1973, 118: 456-63.View ArticlePubMedGoogle Scholar
- Heffez L, Doku HC, Carter BL, Feeney JE: Perspectives on massive osteolysis. Report of a case and review of the literature. Oral Surg Oral Med Oral Pathol. 1983, 55: 331-43. 10.1016/0030-4220(83)90185-8.View ArticlePubMedGoogle Scholar
- Holroyd I, Dillon M, Roberts GJ: Gorham's disease: a case (including dental presentation) of vanishing bone disease. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2000, 89: 125-9. 10.1016/S1079-2104(00)80027-X.View ArticlePubMedGoogle Scholar
- Hsu TS, Cooper LT, Maus TP, Miller EA, Barlow JH, Davis MD: Cutaneous and gastrointestinal tract hemangiomas associated with disappearing bones: Gorham syndrome. Int J Dermatol. 2001, 40: 726-8. 10.1046/j.1365-4362.2001.01281-4.x.View ArticlePubMedGoogle Scholar
- Paley MD, Lloyd CJ, Penfold CN: Total mandibular reconstruction for massive osteolysis of the mandible (Gorham-Stout syndrome). Br J Oral Maxillofac Surg. 2005, 43: 166-8. 10.1016/j.bjoms.2004.09.008.View ArticlePubMedGoogle Scholar
- Pfleger A, Schwinger W, Maier A, Tauss J, Popper HH, Zach MS: Gorham-Stout syndrome in a male adolescent-case report and review of the literature. J Pediatr Hematol Oncol. 2006, 28: 231-3. 10.1097/01.mph.0000203721.83566.e6.View ArticlePubMedGoogle Scholar
- Takahashi A, Ogawa C, Kanazawa T, Watanabe H, Suzuki M, Suzuki N, Tsuchida Y, Morikawa A, Kuwano H: Remission induced by interferon alfa in a patient with massive osteolysis and extension of lymph-hemangiomatosis: a severe case of Gorham-Stout syndrome. J Pediatr Surg. 2005, 40: E47-50. 10.1016/j.jpedsurg.2004.11.015.View ArticlePubMedGoogle Scholar
- Turra S, Gigante C, Scapinelli R: A 20-year follow-up study of a case of surgically treated massive osteolysis. Clin Orthop Relat Res. 1990, 297-302.Google Scholar
- Vigorita VJ, Magitsky S, Bryk E: Gorham's disease: an autopsy report. Clin Orthop Relat Res. 2006, 451: 267-73. 10.1097/01.blo.0000223990.49400.7e.View ArticlePubMedGoogle Scholar
- Devaney K, Vinh TN, Sweet DE: Skeletal-extraskeletal angiomatosis. A clinicopathological study of fourteen patients and nosologic considerations. J Bone Joint Surg Am. 1994, 76: 878-91.PubMedGoogle Scholar
- Shives TC, Beabout JW, Unni KK: Massive osteolysis. Clin Orthop Relat Res. 1993, 267-76.Google Scholar
- Hardegger F, Simpson LA, Segmueller G: The syndrome of idiopathic osteolysis. Classification, review, and case report. J Bone Joint Surg Br. 1985, 67: 88-93.PubMedGoogle Scholar
- Dutheil-Doco A, Ducou le Pointe H, Larroquet M, Josset P, Tournier G, Montagne JP: [Gorham disease with prominent pleuropulmonary manifestation]. J Radiol. 1997, 78: 665-7.PubMedGoogle Scholar
- Leonard JC, Morin C: [Radiological case of the month. Gorham disease of costovertebral localization]. Arch Pediatr. 1997, 4: 893-5. 10.1016/S0929-693X(97)88162-6.View ArticlePubMedGoogle Scholar
- Auge B, Toussirot E, Kantelip B, Wendling D: From polycystic bone angiomatosis to Gorham's disease. Two case-reports and literature review. Rev Rhum Engl Ed. 1998, 65: 201-6.PubMedGoogle Scholar
- Colucci S, Taraboletti G, Primo L, Viale A, Roca C, Valdembri D, Geuna M, Pagano M, Grano M, Pogrel AM, Harris AL, Athanasou NN, Mantovani A, Zallone A, Bussolino F: Gorham-Stout syndrome: a monocyte-mediated cytokine propelled disease. J Bone Miner Res. 2006, 21: 207-18. 10.1359/JBMR.051019.View ArticlePubMedGoogle Scholar
- Devlin RD, Bone HG, Roodman GD: Interleukin-6: a potential mediator of the massive osteolysis in patients with Gorham-Stout disease. J Clin Endocrinol Metab. 1996, 81: 1893-7. 10.1210/jc.81.5.1893.PubMedGoogle Scholar
- Hirayama T, Sabokbar A, Itonaga I, Watt-Smith S, Athanasou NA: Cellular and humoral mechanisms of osteoclast formation and bone resorption in Gorham-Stout disease. J Pathol. 2001, 195: 624-30. 10.1002/path.989.View ArticlePubMedGoogle Scholar
- Franchi A, Bertoni F, Bacchini P, Mourmouras V, Miracco C: CD105/endoglin expression in Gorham disease of bone. J Clin Pathol. 2009, 62: 163-7. 10.1136/jcp.2008.060160.View ArticlePubMedGoogle Scholar
- Hagberg H, Lamberg K, Astrom G: Alpha-2b interferon and oral clodronate for Gorham's disease. Lancet. 1997, 350: 1822-3. 10.1016/S0140-6736(05)63639-2.View ArticlePubMedGoogle Scholar
- Somoza Argibay I, Diaz Gonzalez M, Martinez Martinez L, Ros Mar Z, Lopez-Gutierrez JC: [Heterogenicity of Gorham-Stout syndrome: association with lymphatic and venous malformations]. An Pediatr (Barc). 2003, 58: 599-603. 10.1157/13048084.View ArticleGoogle Scholar
- Hagendoorn J, Padera TP, Yock TI, Nielsen GP, di Tomaso E, Duda DG, Delaney TF, Gaissert HA, Pearce J, Rosenberg AE, Jain RK, Ebb DH: Platelet-derived growth factor receptor-beta in Gorham's disease. Nat Clin Pract Oncol. 2006, 3: 693-7. 10.1038/ncponc0660.PubMed CentralView ArticlePubMedGoogle Scholar
- Kose M, Pekcan S, Dogru D, Akyuz C, Ozcelik U, Ozsurekci Y, Gulhan B, Demircin M, Kiper N: Gorham-Stout Syndrome with chylothorax: successful remission by interferon alpha-2b. Pediatr Pulmonol. 2009, 44: 613-5. 10.1002/ppul.20849.View ArticlePubMedGoogle Scholar
- Bek V, Haicl Z, Kolar J, Bednar B: Radiotherapy in massive angiomatous osteolysis (Gorham-Stout's syndrome). Strahlentherapie. 1981, 157: 813-8.PubMedGoogle Scholar
- Fontanesi J: Radiation therapy in the treatment of Gorham disease. J Pediatr Hematol Oncol. 2003, 25: 816-7. 10.1097/00043426-200310000-00016.View ArticlePubMedGoogle Scholar
- McNeil KD, Fong KM, Walker QJ, Jessup P, Zimmerman PV: Gorham's syndrome: a usually fatal cause of pleural effusion treated successfully with radiotherapy. Thorax. 1996, 51: 1275-6. 10.1136/thx.51.12.1275.PubMed CentralView ArticlePubMedGoogle Scholar
- Dunbar SF, Rosenberg A, Mankin H, Rosenthal D, Suit HD: Gorham's massive osteolysis: the role of radiation therapy and a review of the literature. Int J Radiat Oncol Biol Phys. 1993, 26: 491-7.View ArticlePubMedGoogle Scholar
- Carneiro RS, Steglich V: "Disappearing bone disease" in the hand. J Hand Surg Am. 1987, 12: 629-34.View ArticlePubMedGoogle Scholar
- Handl-Zeller L, Hohenberg G: Radiotherapy of Morbus Gorham-Stout: the biological value of low irradiation dose. Br J Radiol. 1990, 63: 206-8. 10.1259/0007-1285-63-747-206.View ArticlePubMedGoogle Scholar
- Kurczynski E, Horwitz SJ: Response of lymphangiectasis to radiotherapy. Cancer. 1981, 48: 255-6. 10.1002/1097-0142(19810715)48:2<255::AID-CNCR2820480208>3.0.CO;2-A.View ArticlePubMedGoogle Scholar
- Ricalde P, Ord RA, Sun CC: Vanishing bone disease in a five year old: report of a case and review of the literature. Int J Oral Maxillofac Surg. 2003, 32: 222-6. 10.1054/ijom.2002.0306.View ArticlePubMedGoogle Scholar
- Dan'ura T, Ozaki T, Sugihara S, Taguchi K, Inoue H: Massive osteolysis in the pelvis--a case report. Acta Orthop Scand. 1998, 69: 197-8.View ArticlePubMedGoogle Scholar
- Stove J, Reichelt A: Massive osteolysis of the pelvis, femur and sacral bone with a Gorham-Stout syndrome. Arch Orthop Trauma Surg. 1995, 114: 207-10. 10.1007/BF00444264.View ArticlePubMedGoogle Scholar
- Florchinger A, Bottger E, Claass-Bottger F, Georgi M, Harms J: [Gorham-Stout syndrome of the spine. Case report and review of the literature]. Rofo. 1998, 168: 68-76.View ArticlePubMedGoogle Scholar
- Tie ML, Poland GA, Rosenow EC: Chylothorax in Gorham's syndrome. A common complication of a rare disease. Chest. 1994, 105: 208-13. 10.1378/chest.105.1.208.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.